Cargando…
FOXA1, GATA3 and PPARɣ Cooperate to Drive Luminal Subtype in Bladder Cancer: A Molecular Analysis of Established Human Cell Lines
Discrete bladder cancer molecular subtypes exhibit differential clinical aggressiveness and therapeutic response, which may have significant implications for identifying novel treatments for this common malignancy. However, research is hindered by the lack of suitable models to study each subtype. T...
Autores principales: | Warrick, Joshua I., Walter, Vonn, Yamashita, Hironobu, Chung, Eunah, Shuman, Lauren, Amponsa, Vasty Osei, Zheng, Zongyu, Chan, Wilson, Whitcomb, Tiffany L., Yue, Feng, Iyyanki, Tejaswi, Kawasawa, Yuka I., Kaag, Matthew, Guo, Wansong, Raman, Jay D., Park, Joo-Seop, DeGraff, David J. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group
2016
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5141480/ https://www.ncbi.nlm.nih.gov/pubmed/27924948 http://dx.doi.org/10.1038/srep38531 |
Ejemplares similares
-
Maintenance of the bladder cancer precursor urothelial hyperplasia requires FOXA1 and persistent expression of oncogenic HRAS
por: Yee, Christopher H., et al.
Publicado: (2019) -
Repression of transcription factor AP-2 alpha by PPARγ reveals a novel transcriptional circuit in basal-squamous bladder cancer
por: Yamashita, Hironobu, et al.
Publicado: (2019) -
Characterization of Histone Deacetylase Expression Within In Vitro and In Vivo Bladder Cancer Model Systems
por: Buckwalter, Jenna M., et al.
Publicado: (2019) -
Evaluation of PD-L1 and other immune markers in bladder urothelial carcinoma stratified by histologic variants and molecular subtypes
por: Li, Huili, et al.
Publicado: (2020) -
PPARɣ drives IL-33-dependent ILC2 pro-tumoral functions
por: Ercolano, Giuseppe, et al.
Publicado: (2021)